Study #2023-1058
A first-in-human study of the safety, pharmacokinetics, and pharmacodynamics of JNJ88549968, a T-cell redirecting bispecific antibody for CALR-mutated Myeloproliferative Neoplasms
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-88549968
Description
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
Study phase:
Phase I
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-877-424-0935
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.